As anticipated, mice with CCR5-deficient monocytes exhibited significantly reduced tumor burden compared to WT controls (Fig. 5c–d), consistent with a role for CCR5+ monocytes in suppressing anti-tumor immunity. The gene discussed is CCR5; the disease is neoplasm.